ACER Acer Therapeutics Inc

Price (delayed)

$1.36

Market cap

$20.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.39

Enterprise value

$13.16M

Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer's pipeline includes four programs: ...

Highlights
The company's net income fell by 30% QoQ but it rose by 12% YoY
ACER's EPS is down by 29% from the previous quarter but it is up by 27% YoY
Acer Therapeutics's revenue has plunged by 71% from the previous quarter and by 60% YoY
Acer Therapeutics's gross profit has shrunk by 71% QoQ and by 60% YoY

Key stats

What are the main financial stats of ACER
Market
Shares outstanding
15.31M
Market cap
$20.82M
Enterprise value
$13.16M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
54.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
36.55
Earnings
Revenue
$360,000
EBIT
-$20.5M
EBITDA
-$20.42M
Free cash flow
-$6.23M
Per share
EPS
-$1.39
Free cash flow per share
-$0.44
Book value per share
-$0.71
Revenue per share
$0.03
TBVPS
$1.66
Balance sheet
Total assets
$31.47M
Total liabilities
$41.57M
Debt
$13.14M
Equity
-$10.1M
Working capital
-$4.22M
Liquidity
Debt to equity
-1.3
Current ratio
0.85
Quick ratio
0.75
Net debt/EBITDA
0.38
Margins
EBITDA margin
-5,672.7%
Gross margin
100%
Net margin
-5,539.4%
Operating margin
-5,104.3%
Efficiency
Return on assets
-56.9%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-526.9%
Return on sales
-5,694.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACER stock price

How has the Acer Therapeutics stock price performed over time
Intraday
-4.9%
1 week
-2.16%
1 month
-40.35%
1 year
-54.67%
YTD
-40.35%
QTD
-53.1%

Financial performance

How have Acer Therapeutics's revenue and profit performed over time
Revenue
$360,000
Gross profit
$360,000
Operating income
-$18.38M
Net income
-$19.94M
Gross margin
100%
Net margin
-5,539.4%
Acer Therapeutics's net margin has shrunk by 121% YoY
ACER's operating margin has plunged by 105% YoY
Acer Therapeutics's revenue has plunged by 71% from the previous quarter and by 60% YoY
Acer Therapeutics's gross profit has shrunk by 71% QoQ and by 60% YoY

Growth

What is Acer Therapeutics's growth rate over time

Valuation

What is Acer Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
54.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
36.55
ACER's EPS is down by 29% from the previous quarter but it is up by 27% YoY
Acer Therapeutics's revenue has plunged by 71% from the previous quarter and by 60% YoY
The price to sales (P/S) is 4.8% lower than the last 4 quarters average of 56.8

Efficiency

How efficient is Acer Therapeutics business performance
ACER's ROS has plunged by 128% YoY
Acer Therapeutics's return on assets has increased by 44% YoY but it has decreased by 42% QoQ

Dividends

What is ACER's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACER.

Financial health

How did Acer Therapeutics financials performed over time
Acer Therapeutics's total assets is 24% lower than its total liabilities
Acer Therapeutics's total assets has decreased by 29% YoY and by 13% QoQ
Acer Therapeutics's current ratio has decreased by 25% YoY and by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.